The Shotlee Journal
Browse Shotlee articles about Health & Wellness.
Showing 8 / 258 Health & Wellness articles
A major study from Penn Medicine reveals a potential link between GLP-1 medications like Ozempic and a significant reduction in breast cancer risk, offering new hope for preventive care.
The new oral Wegovy formulation has arrived, but hair shedding concerns remain. Discover the science behind the risk and three actionable lifestyle changes to protect your hair health while on semaglutide.
Explore the groundbreaking research linking GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, to a reduced risk of substance use disorders and fewer addiction-related emergencies.
The widespread adoption of Ozempic and Wegovy for weight loss has coincided with a significant rise in calls to poison control centers. This article delves into the research behind this trend, highlighting common mistakes and the importance of proper patient education.
New research is shedding light on how GLP-1 medications, including popular drugs like Ozempic and Wegovy, influence brain pathways that control nausea, thirst, and reward-driven behaviors. This article delves into these findings and discusses potential strategies for managing common side effects.
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
Beyond their well-known benefits for weight loss and diabetes management, popular GLP-1 medications such as Ozempic and Wegovy are now being studied for their potential impact on violent behavior. Emerging research from Rutgers University indicates a surprising link between these drugs and a reduction in actions associated with violence.
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
